Document is current
Any future updates will be listed below
-
Authors
Huijberts, Ilse https://orcid.org/0000-0002-4138-9855
Oostenbrugge, Robert J. van https://orcid.org/0000-0003-1032-9099
Zwam, Wim H. van https://orcid.org/0000-0003-1631-7056
Postma, Alida A. https://orcid.org/0000-0002-1116-054X
Pinckaers, Florentina M.E. https://orcid.org/0000-0002-8336-6897
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 29 September 2025
First Online: 21 October 2025
Declarations
:
: The ethics committee of the Erasmus University Medical Centre, Rotterdam, The Netherlands approved the MR CLEAN LATE trial (MEC-2017-367). The ethics committee of the Maastricht University Medical Centre+, Maastricht, The Netherlands approved the cross-sectional study (MEC-2020-1636).
: Informed consent was obtained from all individual participants included in the study.
: RvO and WvZ report financial support from the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium, all paid to the institution. WHvZ reports speaker fees from Stryker, Cerenovus, Nicolab, Philips, Medtronic, and Microvention, and consulting fees from Philips, all paid to the institution; participated in the advisory boards of WeTrust (Philips) and ANAIS (Anaconda), all paid to the institution; and participated in the advisory board of InExtremis (CHU Montpellier, Montpellier, France), for which no payments were received. AP received an institutional grant from Siemens Healthineers and Bayer Healthcare. IH and FP have no competing interests to declare.
